NeuroBo Pharmaceuticals receives first site IRB approval for obesity trial

NeuroBo Pharmaceuticals has received first site Institutional Review Board – IRB – approval to proceed with the Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor for the treatment of obesity. The company expects to randomize the first patient in Q2. The company expects to report top-line data from the single ascending dose Part 1 in the first half of 2025 and the multiple ascending dose Part 2 in the second half of 2025. The Phase 1 trial is designed to be a randomized, placebo-controlled, double-blind, two-part study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of DA-1726 in obese, otherwise healthy subjects. The primary endpoint will assess the safety and tolerability of DA-1726 by monitoring adverse events, serious adverse events, treatment emergent adverse events and AEs leading to treatment discontinuation. Secondary endpoints include the PK of DA-1726.